Table 2.
FDG Avidity According to WHO Classification
Histology | No. of Patients | FDG Avid (%) |
---|---|---|
HL | 489 | 97-100 |
DLBCL | 446 | 97-100 |
FL | 622 | 91-100 |
Mantle-cell lymphoma | 83 | 100 |
Burkitt's lymphoma | 24 | 100 |
Marginal zone lymphoma, nodal | 14 | 100 |
Lymphoblastic lymphoma | 6 | 100 |
Anaplastic large T-cell lymphoma | 37 | 94-100* |
NK/T-cell lymphoma | 80 | 83-100 |
Angioimmunoblastic T-cell lymphoma | 31 | 78-100 |
Peripheral T-cell lymphoma | 93 | 86-98 |
MALT marginal zone lymphoma | 227 | 54-81 |
Small lymphocytic lymphoma | 49 | 47-83 |
Enteropathy-type T-cell lymphoma | 20 | 67-100 |
Marginal zone lymphoma, splenic | 13 | 53-67 |
Marginal zone lymphoma, unspecified | 12 | 67 |
Mycosis fungoides | 24 | 83-100 |
Sezary syndrome | 8 | 100† |
Primary cutaneous anaplastic large T-cell lymphoma | 14 | 40-60 |
Lymphomatoid papulosis | 2 | 50 |
Subcutaneous panniculitis-like T-cell lymphoma | 7 | 71 |
Cutaneous B-cell lymphoma | 2 | 0 |
Abbreviations: DLBCL, diffuse large B-cell lymphoma; FDG, [18F]fluorodeoxyglucose; FL, follicular lymphoma; HL, Hodgkin lymphoma; MALT, mucosa-associated lymphoid tissue; NK, natural killer.
Only 27% of cutaneous sites.
Only 62% of cutaneous sites.